Effectiveness of antifibrotics on health-related quality of life in patients with interstitial lung disease: a systematic review and meta-analysis.

Ther Adv Respir Dis · 2025 · PMC12580519 · PMID 41174997

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0900

boldest claim

The sentences

borderline significancep = 0.05actually significant

When stratified by the antifibrotic type, a significant increase in fatigue was observed in the pirfenidone group (RR: 1.47, 95% CI: 1.15–1.87; I 2 = 0%), while nintedanib group showed a borderline significance (RR: 1.51, 95% CI: 0.99–2.30, p = 0.05; I 2 = 0%; Supplemental Figure 5 ).

also in 3,162 other papers

a trend toward significancep = 0.06so close (0.05 < p ≤ 0.1)

Similarly, significant results were found in patients with IPF (RR: 1.47, 95% CI: 1.15–1.88; I 2 = 0%), with a trend toward significance in those with non-IPF ILD (RR: 1.50, 95% CI: 0.98–2.28, p = 0.06; I 2 = 0%; Supplemental Figure 5 ).

also in 2,066 other papers

marginally significantp = 0.09so close (0.05 < p ≤ 0.1)

However, pooled data from INPULSIS-1 and 2 ( n = 1,066) suggested only a marginally significant improvement with nintedanib (difference: −1.43 points; 95% CI: −3.09 to 0.23; p = 0.09). 6 The 52-week RCT ( n = 432) demonstrated a significant reduction in SGRQ scores with nintedanib compared with placebo (adjusted mean absolute change from baseline: −0.66 vs 5.46 points; p = 0.007). 24

also in 10,426 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.